Antitumor effects of gossypol on murine tumors.
Since the male antifertility drug, gossypol, was shown to be a specific inhibitor of DNA synthesis at moderately low doses in cultured cells, its antitumor potential has been evaluated in three murine tumor models. The effects of gossypol on tumor growth and the survival of 10- to 12-week-old BDF1 mice bearing mouse mammary adenocarcinoma 755 (Ca 755) or P388 or L1210 leukemias, all injected IP, were measured. At an optimum dose of 0.5 mg/mouse given as a single injection at 2 days (48 h) after the inoculation of 10(5) Ca 755 tumor cells, gossypol rendered 66% of the mice free of tumor cells, whereas the remaining 34% died of drug toxicity. The survival rate decreased sharply at doses on either side of the optimum. At suboptimal doses a major proportion of the tumor-bearing mice died of tumor, whereas at higher doses all the animals died of drug toxicity. In other words, the effective dose range of gossypol was rather narrow. The rapidly proliferating mouse leukemias, P388 and L1210, failed to respond to gossypol. Histopathological studies of various organs in the gossypol-treated mice revealed no consistent lesions that could give an indication of organ-specific toxicity of gossypol. The reduction in the myeloid series in the bone marrow of gossypol-treated mice may have been due to depletion rather than direct toxic effect. Further studies are essential to evaluate this compound with regard to its antitumor activity in other murine models.
D000818:Animals; D002452:Cell Count; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006072:Gossypol / Q000627:therapeutic use* / Q000633:toxicity; D007939:Leukemia L1210 / Q000188:drug therapy; D007941:Leukemia P388 / Q000188:drug therapy; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology; D010529:Peritoneal Cavity / Q000473:pathology
D006072:Gossypol